A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer

Vantictumab is a fully human monoclonal antibody that inhibits Wnt pathway signaling through binding FZD1, 2, 5, 7, and 8 receptors. This phase Ib study evaluated vantictumab in combination with nab-paclitaxel and gemcitabine in patients with untreated metastatic pancreatic adenocarcinoma. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, S. Lindsey, Cardin, Dana B., Shahda, Safi, Lenz, Heinz-Josef, Dotan, Efrat, O’Neil, Bert H., Kapoun, Ann M., Stagg, Robert J., Berlin, Jordan, Messersmith, Wells A., Cohen, Steven J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211194/
https://www.ncbi.nlm.nih.gov/pubmed/31338636
http://dx.doi.org/10.1007/s10637-019-00824-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211194/
https://www.ncbi.nlm.nih.gov/pubmed/31338636
http://dx.doi.org/10.1007/s10637-019-00824-1

Ejemplares similares